Hepatitis C Maintenance of Certification 2015
The IDSA Hepatitis C MOC Module 2015 is a tool for self-evaluation of medical knowledge in Hepatitis C. The module consists of 45 multiple-choice questions; the majority contains case information and all include educational links and answer rationales. American Board of Internal Medicine (ABIM) diplomates who successfully complete this activity are eligible to receive 15 points toward the self-evaluation of medical knowledge requirement. Participants may also earn a maximum of 15.0 AMA PRA Category 1 Credit(s).™
This activity was reviewed and revised in December, 2020.
This activity is supported by an unrestricted educational grant from Gilead Sciences, Inc.
This CME activity is intended for infectious diseases physicians, ID academicians, and internal medicine physicians.
At the conclusion of this activity, participants will be able to:
- Identify gaps in infectious diseases medical knowledge where further study is needed for board preparation and patient management
- Improve competence in the area of infectious diseases medicine regarding diagnosis, treatments, and other aspects of patient management
- Evaluate and revise patient management strategies
- Improve clinical decision-making skills in infectious diseases medicine
Faculty and Disclosures
Michael S Saag, MD, Chair, Professor of Medicine, University of Alabama at Birmingham; Staff physician, UAB Health Services; Advisory/Consultant Role: Ardea, Avexa; BIPI, BMS, Gilead, GSK, Merck, Pfizer, Tibotec, Jannsen, Monogram, ViiV, Vertex; Research grants: CDC, NIH / NIAID; Editor, Sanford Guide; Editor, AIDS Therapy, 3rd Edition
Carol L Brosgart, MD, Senior Advisor on Science and Policy, Viral Hepatitis, CDC Foundation; Advisory/Consultant Role: Astex, Dynavax, Theravance; Stocks, bonds: Juvaris; Board member: Tobira, Alios
Eliot W Godofsky, MD, Chief Operating Officer/Director, Hepatitis Clinic, Pointe West Infectious Diseases; Advisory/Consultant Role (honoraria): Vertex Pharmaceuticals; Advisory/Consultant Role: Merck
Camilla S Graham, MD, Staff Physician, Beth Israel Deaconess Medical Center; former Vice President and Head, Global Medical Affairs, Vertex Pharmaceuticals, Inc.
Arthur Kim, MD, Assistant Professor of Medicine, Director of Viral Hepatitis Clinic, Division of Infectious Diseases, Massachusetts General Hospital. Honoraria: Vertex Pharmaceuticals; Consultant/Advisory Board: Gilead, Abbvie; research support / grant for clinical trial: Bristol Myers Squibb.
Alexander Kuo, M.D, Associate Clinical Professor of Medicine; Director of Hepatology; Medical Director, Liver Transplant Program, University of California, San Diego; Advisor/Consultant role: Gilead. Research funding: Gilead, AbbVie, Merck
Michael Melia, MD, Assistant Professor of Medicine, The Johns Hopkins University; multiple grants from Merck, Gilead, Bristol-Myers Squibb, Janssen and Janssen, AbbVie. Funds paid to Johns Hopkins University
Susanna Naggie, MD, Assistant Professor of Medicine, Duke University. Advisory/Consultant Role: Vertex Pharmaceuticals, Inc., Gilead Sciences, Inc; Abbott Laboratories, Janssen
David Thomas, MD, Chief of Infectious Diseases, Johns Hopkins University. Advisory/Consultant Role: Gilead, Janssen, Merck
Kathleen Matikonis, MA, IDSA Senior Education Officer; nothing to disclose
Rachel Shnekendorf, MPH, IDSA Senior Education Officer; nothing to disclose
Harry Gallis, MD, Consulting Professor of Medicine, Duke University Medical Center; Advisor/Consultant: Meniscus Education, Fortis-Spectrum; CME Consultant to American College of Cardiology, North Carolina Medical Society
All relevant financial relationships have been mitigated.
© Copyright 2015 IDSA. All rights reserved. Questions in this module may not be copied, distributed or adapted.
In support of improving patient care, IDSA is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement
IDSA designates this enduring material for a maximum of 15 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Physician participation information will be shared with ABIM through ACCME PARS.
- 15.00 ABIM MOC II
- 15.00 AMA PRA Category 1 Credit(s)™